ObsEva (OBSV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock OBSV vs. SNYR, ELEV, PULM, TNXP, MRNS, IRD, VRCA, UBX, AKTX, and GDTCShould you be buying ObsEva stock or one of its competitors? The main competitors of ObsEva include Synergy CHC Corp. (Uplisting) (SNYR), Elevation Oncology (ELEV), Pulmatrix (PULM), Tonix Pharmaceuticals (TNXP), Marinus Pharmaceuticals (MRNS), Opus Genetics (IRD), Verrica Pharmaceuticals (VRCA), Unity Biotechnology (UBX), Akari Therapeutics (AKTX), and CytoMed Therapeutics (GDTC). These companies are all part of the "pharmaceutical products" industry. ObsEva vs. Synergy CHC Corp. (Uplisting) Elevation Oncology Pulmatrix Tonix Pharmaceuticals Marinus Pharmaceuticals Opus Genetics Verrica Pharmaceuticals Unity Biotechnology Akari Therapeutics CytoMed Therapeutics Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) and ObsEva (NASDAQ:OBSV) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, dividends, profitability, earnings, media sentiment, valuation and risk. Do analysts recommend SNYR or OBSV? Synergy CHC Corp. (Uplisting) presently has a consensus target price of $10.00, indicating a potential upside of 244.83%. Given Synergy CHC Corp. (Uplisting)'s stronger consensus rating and higher probable upside, research analysts clearly believe Synergy CHC Corp. (Uplisting) is more favorable than ObsEva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC Corp. (Uplisting) 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer SNYR or OBSV? ObsEva received 317 more outperform votes than Synergy CHC Corp. (Uplisting) when rated by MarketBeat users. However, 66.67% of users gave Synergy CHC Corp. (Uplisting) an outperform vote while only 50.08% of users gave ObsEva an outperform vote. CompanyUnderperformOutperformSynergy CHC Corp. (Uplisting)Outperform Votes266.67% Underperform Votes133.33% ObsEvaOutperform Votes31950.08% Underperform Votes31849.92% Does the media refer more to SNYR or OBSV? In the previous week, Synergy CHC Corp. (Uplisting) had 1 more articles in the media than ObsEva. MarketBeat recorded 1 mentions for Synergy CHC Corp. (Uplisting) and 0 mentions for ObsEva. Synergy CHC Corp. (Uplisting)'s average media sentiment score of 0.94 beat ObsEva's score of 0.00 indicating that Synergy CHC Corp. (Uplisting) is being referred to more favorably in the media. Company Overall Sentiment Synergy CHC Corp. (Uplisting) Positive ObsEva Neutral Which has stronger valuation & earnings, SNYR or OBSV? Synergy CHC Corp. (Uplisting) has higher revenue and earnings than ObsEva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynergy CHC Corp. (Uplisting)$26.01M0.97N/AN/AN/AObsEva$20.11M0.00-$58.38M-$0.92N/A Do institutionals and insiders hold more shares of SNYR or OBSV? 17.5% of ObsEva shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is SNYR or OBSV more profitable? Synergy CHC Corp. (Uplisting)'s return on equity of 0.00% beat ObsEva's return on equity.Company Net Margins Return on Equity Return on Assets Synergy CHC Corp. (Uplisting)N/A N/A N/A ObsEva N/A -416.36%-92.01% SummarySynergy CHC Corp. (Uplisting) beats ObsEva on 10 of the 13 factors compared between the two stocks. Remove Ads Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBSV vs. The Competition Export to ExcelMetricObsEvaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.94M$6.90B$5.64B$7.84BDividend YieldN/A2.74%4.59%4.01%P/E Ratio-0.117.1723.4118.71Price / SalesN/A218.12387.6790.64Price / CashN/A65.6738.1734.64Price / BookN/A6.386.894.23Net Income-$58.38M$142.12M$3.20B$247.34M ObsEva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150SNYRSynergy CHC Corp. (Uplisting)3.5914 of 5 stars$3.58+0.8%$10.00+179.3%N/A$31.16M$26.01M0.0040ELEVElevation Oncology2.4129 of 5 stars$0.53-1.3%$6.83+1,199.4%-94.9%$31.14MN/A-0.6440PULMPulmatrix0.3394 of 5 stars$8.39-0.8%N/A+310.9%$30.62M$10.01M-3.1820Earnings ReportTNXPTonix Pharmaceuticals2.4453 of 5 stars$16.28+8.5%$1,100.00+6,656.8%-96.6%$30.43M$11.29M0.0050Short Interest ↑Gap DownMRNSMarinus Pharmaceuticals2.3278 of 5 stars$0.55-0.2%$4.79+771.6%-93.9%$30.32M$30.99M-0.22110Analyst ForecastNews CoverageIRDOpus Genetics2.3297 of 5 stars$0.94+0.7%$8.00+749.6%N/A$29.72M$8.38M-0.8614Upcoming EarningsVRCAVerrica Pharmaceuticals4.2374 of 5 stars$0.65+21.1%$9.50+1,360.4%-92.7%$29.66M$7.57M-0.3640UBXUnity Biotechnology4.1159 of 5 stars$1.75-1.1%$7.33+319.0%-30.5%$29.52M$240,000.00-1.3460Analyst ForecastAnalyst RevisionAKTXAkari TherapeuticsN/A$1.10+1.9%N/A-31.4%$29.25MN/A0.009Upcoming EarningsAnalyst ForecastGDTCCytoMed Therapeutics2.4732 of 5 stars$2.65+6.9%$5.00+88.7%+0.4%$28.99MN/A0.00N/AShort Interest ↓Positive News Remove Ads Related Companies and Tools Related Companies Synergy CHC Corp. (Uplisting) Alternatives Elevation Oncology Alternatives Pulmatrix Alternatives Tonix Pharmaceuticals Alternatives Marinus Pharmaceuticals Alternatives Opus Genetics Alternatives Verrica Pharmaceuticals Alternatives Unity Biotechnology Alternatives Akari Therapeutics Alternatives CytoMed Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBSV) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ObsEva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
